IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations

Stock News

2025/09/08

According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.

Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1161475716"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1161475716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1161475716?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161475716","market":"fut","top_or_hot":-1,"title":"IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations","media":"Stock News","content":"<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO News | Legend Biotech (LEGN.US) Reportedly Considering Second Listing Outside US, Hong Kong Among Potential Locations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-08 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.</p>\n<p>Legend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1161475716","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161475716","pubTimestamp":1757297537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LEGN":"传奇生物","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"IPO快讯|传奇生物(LEGN.US)据报道考虑在美国、香港以外的潜在地点进行第二次上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEGN":1},"content_text":"According to reports, Legend Biotech (LEGN.US) is considering a second listing outside the United States due to strong investor interest in pharmaceutical companies. Sources familiar with the matter indicate that potential listing locations include Hong Kong, Singapore, and London. A second listing in Hong Kong, in particular, could help boost Legend Biotech's valuation. The report notes that Legend Biotech is still in the consideration phase and may decide not to proceed with a second listing. Representatives from Legend Biotech declined to comment.\nLegend Biotech was founded in 2014 and went public on the US NASDAQ in 2020. The company specializes in CAR-T cell immunotherapy for cancer treatment, with its flagship product ciltacabtagene autoleucel already approved by the US FDA for market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}